title: Phosphate excretion is decreased in older cardiac patients with normal kidney function: an emerging dietary risk factor?
abstract: Serum phosphate independently predicts cardiovascular events and mortality. Sixteen healthy adults and 9 adults with cardiovascular disease (CVD) ingested 500 mg of sodium phosphate after an over-night fast. In control subjects, the urine phosphate/creatinine ratio was significantly higher at 2 h (3.12 ± 1.02) than at baseline (1.98 ± 0.58, p < 0.001) but no change was observed in CVD patients. Decreased postprandial urinary excretion of phosphate could accelerate vascular calcification and may be an under-recognized risk factor for CVD.
authors.affiliation: a Department of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
authors.forename: Alexis
authors.initials: A
authors.lastname: Jozefacki
authors.affiliation: a Department of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
authors.forename: Christine A
authors.initials: CA
authors.lastname: White
authors.affiliation: b Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.
authors.forename: Navid S
authors.initials: NS
authors.lastname: Shobeiri
authors.affiliation: c Clinical Research Centre, Kingston General Hospital, and Department of Public Health Sciences, Kingston, ON K7L 3N6, Canada.
authors.forename: Wilma M
authors.initials: WM
authors.lastname: Hopman
authors.affiliation: a Department of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
authors.forename: Amer M
authors.initials: AM
authors.lastname: Johri
authors.affiliation: b Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Adams
authors.affiliation: a Department of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.|b Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.
authors.forename: Rachel M
authors.initials: RM
authors.lastname: Holden
mesh_terms: D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000652:urine*; D016022:Case-Control Studies; D003404:Creatinine / Q000652:urine; D004032:Diet; D004305:Dose-Response Relationship, Drug; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000652:urine; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000008:administration & dosage / Q000009:adverse effects / Q000652:urine*; D010865:Pilot Projects; D019518:Postprandial Period; D012307:Risk Factors; D061205:Vascular Calcification / Q000209:etiology / Q000652:urine; D055815:Young Adult
chemical_list: D010710:Phosphates; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D003404:Creatinine; C512478:EGFR protein, human; D066246:ErbB Receptors; C018279:sodium phosphate
keywords: calcification vasculaire; cardiovascular disease; facteur de croissance des fibroblastes 23; fibroblast growth factor 23; fraction excrétée de phosphate; fractional excretion of phosphate; maladie cardiovasculaire; phosphate; vascular calcification